FDA Wants Cardiovascular Adverse Event Data Broadly Available For Research
Executive Summary
FDA outlined two proposals to better monitor cardiovascular adverse events, mainly focusing on means to create more comprehensive links between physicians, industry and academia, at a recent Drug Information Association conference